Neuronal IL-17 controls *C. elegans* developmental diapause through CEP-1/p53

Abhishiktha Godthi[1,2,], Sehee Min[1,2,], Srijit Das[1], Johnny Cruz-Corchado[1,2], Andrew Deonarine[1],

Kara Misel-Wuchter [3], Priya D. Issuree [3] and Veena Prahlad[1,2] *

Affiliations: [1]Department of Cell Stress Biology

Roswell Park - Comprehensive Cancer Center

Elm and Carlton Streets

CGP-BLSC   L3-307

Buffalo, New York 14263

[2]Department of Biology,

338 Biology Building East,

143 Biology Building, Iowa City, IA 52242-1324.

[3]Department of Internal Medicine,

503 Eckstein Medical Research Building,

431 Newton Road, Iowa City, IA 52242

* Corresponding author name: Veena Prahlad

Corresponding author email**:** veena.prahlad@roswellpark.org

Author Contributions

All authors designed the study, performed experiments, analyzed data, and drafted the manuscript. P.D.I coordinated the mammalian experiments; V.P. coordinated *C. elegans* experiments and the project. All authors approved the final version of the manuscript.

Declaration of Interests

The authors declare no competing interests.

Classification

Biological Sciences; Developmental Biology

Keywords:

***C. elegans* p53/ CEP-1, dauer, IL-17, development, immunometabolomic, nutrient signaling.**

This PDF file includes:

Main Text
Figures 1 to 6

Supporting Information:
Extended Methods
Supplementary Figure S1-S14 including Extended Text 1-4
Supplementary Datasets S1 to S14.

Significance. Development in a metazoan requires that the division and differentiation of diverse cells be coordinated with nutrient availability. We show that one mechanism by which this occurs in *C. elegans* is through signaling by the neuronal IL-17 cytokine, ILC-17.1, and its control over p53/CEP-1.   In the presence of food, ILC-17.1 release suppresses p53/CEP-1 and allows reproductive growth; decreased ILC-17.1 signaling activates p53/CEP-1-dependent transcription and metabolic programs, leading to the reversible arrest of larvae as quiescent dauers.   Our studies suggest an ancestral function of IL-17 is linking nutrient availability to energy metabolism and growth. They reveal a DNA damage-independent function of p53/CEP-1 in invertebrate development.   Finally, our studies support the existence of a previously undescribed dauer pathway in *C. elegans*.

Abstract. During metazoan development, how cell division and metabolic programs are coordinated with nutrient availability remains unclear. Here, we show that nutrient availability signaled by the neuronal cytokine, ILC-17.1 switches *C. elegans* development between reproductive growth and dormancy by controlling the activity of the tumor suppressor p53 ortholog, CEP-1. Specifically, upon food availability, ILC-17.1 signaling by amphid neurons promotes glucose utilization and suppresses CEP-1/p53 to allow growth. In the absence of ILC-17.1, CEP-1/p53 is activated, upregulates cell-cycle inhibitors, decreases phosphofructokinase and cytochrome C expression, and causes larvae to arrest as stress-resistant, quiescent dauers. We propose a model whereby ILC-17.1 signaling links nutrient availability and energy metabolism to cell cycle progression through CEP-1/p53. These studies describe ancestral functions of IL-17s and the p53-family of proteins and are relevant to our understanding of neuroimmune mechanisms in cancer. They also reveal a DNA damage-independent function of CEP-1/p53 in invertebrate development and support the existence of a previously undescribed *C. elegans* dauer pathway.

During metazoan development, nutrient availability is coordinated with the division, growth and

metabolic activity of individual cells through cell-cell communication. This is also the case in the

invertebrate *C. elegans*, a free-living bacterivore, which displays a dramatic developmental

plasticity to ensure that its growth and reproduction match available resources(1-10). When *C.*

elegans larvae hatch under optimal conditions (at 20°C, low population densities, on abundant

food) they develop continuously into reproducing adults. However, if they hatch under suboptimal

conditions, such as in the paucity of food, at high population densities, or high ambient

temperatures, larvae implement an alternative developmental program and arrest as quiescent,

stress-resistant larvae called 'dauer' larvae. Dauer larvae display metabolic and organismal

phenotypes specialized for dispersal and survival, and can remain arrested in this state for months

to resume development into reproductive adults when favorable conditions return(1-10). Previous

studies have identified molecular pathways that mediate the dauer decision, showing that growth

promoting molecules like insulins, transforming β growth factor (TGFβ/DAF-7) and lipid based

dafachronic acid hormones are released by sensory neurons and other cells to license continued

development; adverse environments inhibit these growth promoting signals and trigger dauer

arrest(1-11). A number of quantitative trait loci (QTL) also modulate dauer (12). Yet, how the

dauer entry decision results in a coordinated change in cell fates across different tissues and is

linked with the systemic shut-down of anabolic pathways remains poorly understood.

An important group of proteins that mediate cell-cell communication and metabolism in metazoa

are secreted proteins called cytokines(13, 14). The IL-17 cytokines constitute a family of

proinflammatory cytokines, highly conserved across animal phyla. In mammals, these cytokines

are released by specialized immune cells to activate immune surveillance, enhance barrier

function, promote wound healing, and play crucial immunometabolic roles in maintaining energy

homeostasis(15). In humans, IL-17s also promote cancers and autoimmune disease such as

psoriasis(16, 17). Here, we show that the *C. elegans* IL-17 ortholog, ILC-17.1, signals food

availability, and coordinates cell division with metabolism by controlling the activity of the *C.*

elegans tumor suppressor p53 ortholog, CEP-1. Specifically, neuronal ILC-17.1 suppresses CEP-

1/p53 activity in the presence of food to license growth. Upon the loss of ILC-17.1 signaling, CEP-

1/p53 is activated, and remarkably, this switches whole organism development from continuous

growth to dormancy. The p53-like tumor suppressor genes are found in all multicellular animals

where they prevent the transmission of damaged DNA by activating a multifaceted program that

controls cell cycle checkpoints, mediates reversible growth arrest or apoptosis, and controls

metabolic flux (18-22). Our studies show that these functions of CEP-1/p53 also act, in the

absence of DNA damage, to control developmental quiescence of *C. elegans*, suggesting that

the developmental function of the p53- gene family could have shaped their evolution(23-25).

Results

ILC-17.1 is released by *C. elegans* amphid neurons in response to food and prevents dauer

arrest.

C. elegans express three IL-17 orthologs(26, 27). Of these, ILC-17.1 is a neuromodulator that is

expressed by a subset of specialized sensory neurons with epithelial properties called amphid

neurons, that are exposed to the environment(26-28). We discovered that a deletion in *ilc-17.1,*

syb5296, that removes almost all the coding sequence (2173bp out of 2980 bp; Supplementary

Fig. S1a) and abolishes mRNA expression (Supplementary Fig. S1b) caused larvae to

constitutively enter the dauer state (Figure 1a, b; Supplementary Fig. S1c, d). Dauer larvae can

be identified by their growth arrest and distinct morphology characterized by specialized cuticular

structures called alae, a constricted pharynx, arrested germ line, decreased pharyngeal pumping

rates, and detergent (1% SDS) resistance(3-9). *ilc-17.1*(*syb5296*)X dauer larvae displayed all

these features (Supplementary Fig. S1e-j). Even at 20°C, *ilc-17.1* deleted larvae entered the

dauer state transiently: approximately 30% (31.2 ±5%) were SDS-resistant 48 hours post-

hatching on OP50 bacteria, and most larvae exited dauer and become reproductive adults by 72

hrs. (Supplementary Fig. S1c, d). Under the same conditions, none of the wild-type larvae were

detergent resistant, nor did they arrest as dauers. However, as with other mutations that promote

dauer entry(3, 4, 29), the dauer arrest of *ilc-17.1* deletion mutants was dramatically accentuated

at the slightly higher ambient temperature of 25°C, which still supported the growth of all wild-type

larvae into reproductive adults, but caused practically 100% of larvae lacking *ilc-17.1* to enter and

persist in the arrested dauer state for days (Fig.1a-d).

Ilc-17.1 has not been identified in previous genetic screens for dauer pathway genes(3, 5, 30-32).

Therefore, although no off-target effects using CRISPR have been observed in *C. elegans* even

after whole genome sequencing (33-35), we conducted additional experiments to confirm the role

of *ilc-17.1* in dauer entry, by (i) examining the developmental phenotype of another independently

generated CRISPR deletion in *ilc-17.1, syb5297* (loss of 2188 bp of 2980 bp; Supplementary Fig.

S1a), (ii) backcrossing *ilc-17.1 (syb5296)* mutants, and (iii) downregulating *ilc-17.1* and its

receptor(26, 27) in a wild-type (N2) background using RNA interference (RNAi) and auxin-induced

degradation (AID). Like *ilc-17.1* (*syb5296*), *ilc-17.1* (*syb5297*) created using a different guide RNA

also displayed a completely penetrant dauer arrest at 25°C (Fig. 1a, b; Material and Methods).

Not surprisingly, CRISPR alone did not trigger dauer arrest, and a similarly large CRISPR-induced

deletion in a related gene *F25D1.3, syb7367* (loss of 1475 bp of 1642 bp) did not trigger dauer

arrest (Supplementary Fig. S1k). *ilc-17.1* (*syb5296*) larvae continued to arrest as dauers after

they were backcrossed twice into a wild-type background (Supplementary Fig. S1k). In addition,

RNAi-mediated downregulation of *ilc-17.1* in wild-type (N2) animals, but not control RNAi

treatment, caused a small but significant number of larvae to arrest as SDS-resistant dauers

(Supplementary Fig. S1l). ILC-17.1 signals though cytokine receptors which in *C. elegans*

consists of ILCR-1/ILCR-2(26, 27). The ILCR-2 subunit is widely expressed and readily visible in

the pharynx, hypodermis, intestine, neurons and germ line, as determined using a bicistronic SL2

cassette to tag the *ilcr-2* receptor at its endogenous locus with GFP (Supplementary Fig. S2a-g).

Downregulation of *ilcr-2* through RNAi in wild-type larvae also caused over one-third, 39.6% ±

4%, to arrest as dauers and did not alter the dauer entry of *ilc-17.1* deleted larvae (Fig. 1e). RNAi

is generally insufficient to induce dauer arrest even with known dauer pathway genes(3).

Therefore, the RNAi-induced dauer entry of larvae exposed to *ilc-17.1* or *ilcr-2* RNAi was not only

statistically significant, but also strongly supportive of the role of the *ilc-17.1* pathway in dauer.

ilcr-2 RNAi downregulated *ilcr-2* expression across all somatic and germline tissues, albeit to

variable extents (Supplementary Fig.S2h-m).   Therefore, as additional confirmation, and to

identify the tissues where ILCR-2 signaling was required to promote continuous development, we

used the AID system to degrade the endogenous ILCR-2 receptor in individual tissues (Fig. 1f).

We targeted the nervous system (using the *rgef-1p* promoter), pharynx (*myo-2p*), hypodermis

(*col-10p)*, muscle (*unc-54p*), all somatic cells (*eft-3p*) and the germ line (*mex-5p*) individually,

using animals that expressed Transport Inhibitor Response 1 (TIR1) in these tissues and

endogenous *ilcr-2* fused to an AID degron. Degradation of ILCR-2 in the pharynx or in the nervous

system alone caused some larvae to arrest as dauers (Fig. 1g). Degradation of ILCR-2 in the

muscle, hypodermis or germ line alone had no effect (Fig. 1g). Blue Fluorescent Protein (BFP),

which served as a proxy for AID, was reduced to undetectable levels upon auxin exposure in a

similar percentage of larvae in all cases (Supplementary Fig. S2n), and thus did not explain the

differences in dauer entry seen upon ILCR-2 degradation in the different tissues. Control larvae

of the same genotype, not exposed to auxin, did not arrest as dauers. Thus, the loss of ILCR-2

receptors in the nervous system or pharynx was sufficient to induce the dauer arrest in a subset

of animals.

Surprisingly, degrading ILCR-2 using TIR1 expressed under the pan-somatic *eft-3* promoter,

which is expressed in somatic cells such as neurons, pharyngeal cells, intestine, hypodermis, and

muscle, but not in the germ line, was less effective in inducing dauer arrest than *ilcr-2* RNAi, or

degradation in the pharynx or nervous system alone: only 1.9 ± 0.8 % arrested as dauers

compared to 39.6% ± 4% with *ilcr-2* RNAi, and 16.3 ± 1.1 % and 11.3 ± 1.5 % upon neuronal or

pharyngeal AID (Fig. 1g). A logical hypothesis which requires future testing is that downregulation

of ILCR-2 elicits complex tissue cross-talk, whereby germline-specific ILCR-2 degradation alone,

while insufficient to trigger dauer arrest (e.g. *mex-5p::TIR1*), might synergize with knock-down in

somatic tissue to promote dauer arrest mirroring the effects observed with *ilcr-2* RNAi. Likewise,

decreased ILC-17.1 signaling in some tissues upon pan-somatic ILCR-2 degradation using the

eft-3 promoter, might antagonize the dauer-inducing effects of degradation in the pharynx or

nervous system. Although more in-depth studies are required to understand the tissue-

requirements, taken together, these observations support the role of ILC-17.1 signaling through

the ubiquitously expressed ILCR-2 receptors in the dauer pathway. They also suggest that during

normal development ILC-17.1 signaling may elicit complex inter-tissue crosstalk to promote the

growth of larvae into reproducing adults or trigger their dauer arrest.

ilc-17.1 mRNA expression is restricted to a small subset of neurons: only a pair of amphid sensory

neurons (ASE) and two pairs of interneurons (AUA and RMG) expressed transgenic *ilc-17.1*

reporter constructs in a previous study (26), and a few dye-filling amphid neurons expressed

mCherry as a bicistronic SL2 cassette along with *ilc-17.1* mRNA from the endogenous *ilc-17.1*

locus, in our studies (Fig. 1h; Supplementary Fig. S3a-g). The dauer phenotype of *ilc-17.1*

deletion mutants could be rescued by re-expressing *ilc-17.1* under the control of its own promoter

(Fig.1b and Supplementary Fig. S3h; see Supplementary Fig. S3i for expression levels of rescue

construct in comparison to the endogenous gene). The extent of rescue was significant, although

modest on OP50 (Fig.1b), but was higher on HT115 bacteria where ILC-17.1 re-expression

rescued approximately 63.6% of the *ilc-17.1* deleted larvae from dauer arrest (Supplementary

Fig. S3h). Re-expressing *ilc-17.1* ectopically in *ilc-17.1* deleted larvae, remote from its normal

site of expression, using the muscle-specific *unc-54* promoter (Supplementary Fig. S3j-t), also

rescued dauer arrest of *ilc-17.1* deleted larvae (Fig.1b and Supplementary Fig. S3h), and RNAi

mediated downregulation of *ilcr-2* reduced the percentage of *ilc-17.1* larvae that were rescued by

ectopically re-expressing ILC-17.1 (Supplementary Fig. S3h). The diet-dependence of rescue

was not observed with ectopically expressed *ilc-17.1* (Fig.1b and Supplementary Fig. S3h). The

effects of AID-induced knockdown of ILCR-2 in different tissues were also similar when larvae

were fed HT115 bacteria instead of OP50 (Supplementary Fig. S3u and Fig.1g). This suggested

that the role of ILC-17.1 signaling in dauer might be related to food, a prominent modulator of the

dauer decision(3-9), and that the ILC-17.1 ligand, and perhaps not the *ILCR-2* receptor *per se*,

could be responsive to the food signals.

To directly examine whether ILC-17.1 responded to food, we immunolocalized ILC-17.1 protein

tagged at its endogenous locus using a HA-tag, in larvae that were hatched in the absence or

presence of food (OP50; Fig 1h-l). While the site of *ilc-17.1* expression was not apparently altered

by the presence of food, as detected by mCherry expression that remained restricted to amphid

neurons (Fig. 1i, k), ILC-17.1 protein was present outside the amphid neurons, concentrated in

the pharynx when larvae were exposed to food (Fig 1l), but not when larvae hatched in the

absence of food (Fig.1j, quantification in Supplementary Fig. S3v; negative controls Fig. 1m,n).

This suggested that ILC-17.1 protein was released from its site of expression in amphid neurons,

to be either selectively translated or retained by the pharynx in response to food signals [we could

not reliably detect ILC-17.1 protein in distal tissues such as the intestine or coelomocytes]. The

secretion of ILC-17.1 protein was also supported by immunolocalization studies on the muscle-

expressed ILC-17.1 protein which, although expressed under a well-characterized muscle-

specific promoter (i.e. *unc-54*), could be constitutively detected outside muscle cells, throughout

the animal (Supplementary Fig. S3m-t). This release of the ectopically expressed ILC-17.1 was

not obviously affected by the absence of food (Supplementary Fig.S3q-t). These studies together

showed that ILC-17.1 was released from its locus of expression in response to food, consistent

with its being secreted, and that the ILC-17.1 signal, transduced through the ILCR-2 receptors in

the neurons and/or pharyngeal muscle, acted cell non-autonomously to control the growth of *C.*

elegans.

Sequencing total RNA (RNA-seq) extracted from bleach synchronized larvae grown for 32-36

hours at 25°C when *ilc-17.1* mutant larvae were *en route* to dauer arrest, and wild-type larvae

were late L2s *en route* to developing into reproducing adults, showed that *ilc-17.1* mutant larvae

expressed the molecular signatures of dauer larvae(6, 36-38) that were distinct from wild-type

larvae and from *ilc-17.1* deletion mutants that re-expressed ILC-17.1 (Supplementary Figure S4a;

Datasets S1-S3). This signature consisted of the downregulation of anabolic processes such as

DNA replication and ribosome biogenesis (Fig. 1o), upregulation of catabolic processes and

stress responses such as autophagy, fatty acid metabolism, glutathione metabolism, and

xenobiotic defense pathways (Fig. 1p) and the expression of dauer-specific collagen genes that

differ from the collagens expressed during continuous development(39) (Fig. 1q; Dataset S4). We

evaluated whether the gene expression profile of the *ilc-17.1* deleted dauers was similar to

previously described *C. elegans* dauers that accumulate in the population upon starvation or

crowding by comparing our RNA-seq data with published datasets (38). Consistent with a role

for ILC-17.1 in signaling nutrient availability, the expression profile of *ilc-17.1* deleted larvae was

more closely correlated to dauer larvae generated by starvation(38) (Supplementary Fig. S4b),

compared to ascaroside induced dauers(37) (Supplementary Fig. S4c; Datasets S5, S6). These

differences were surprising and suggest that the trigger and route of dauer entry could determine

their gene expression profiles (40, 41).

ILC-17.1 loss activates CEP-1/p53 to trigger dauer entry through the activation of DAF-

16/FOXO, DAF-3/SMAD-DAF-5/Ski complex and steroid hormone pathways.

To understand how the loss of ILC-17.1 was triggering dauer entry we first considered the

possibility that, because of its role as a neuromodulator(26), the lack of *ilc-17.1* prevented larvae

from finding or ingesting food. However, this did not seem to be the case (Supplementary Fig. S5;

see Extended Text 1 for details). Therefore, to answer how the loss of ILC-17.1 triggered dauer

entry, we adopted a genetic approach (2-11, 29). In *C. elegans*, insulins released in the presence

of food act through the sole insulin-like receptor, DAF-2, antagonize the activation of the Forkhead

transcription factor DAF-16, and promote continuous growth: loss of DAF-2 signaling leads to

DAF-16 activation and dauer entry(2-11, 29). Likewise, TGFβ/DAF-7 ligands antagonize the

DAF-3/SMAD-DAF-5/Ski transcription factor complex to permit continuous growth: inhibition of

DAF-7 activates DAF-3/SMAD-DAF-5/Ski and leads to dauer arrest(2-11, 29). Both insulins and

TGF-β promote the synthesis of sterol based dafachronic acid (DA) hormones that act through

the nuclear hormone receptor, DAF-12, to support adult development(2-11, 29). Loss of DA

pathway components also triggers dauer arrest, and providing exogenous DA to, or decreasing

DAF-12 activity in, animals deficient in insulin or TGFβ signaling, can bypass their dauer arrest(3,

42). Finally, a mutation in a transmembrane guanylyl cyclase *daf-11* that causes chemosensory

defects also triggers dauer arrest(3, 43). *ilc-17.1* deletion mutants lacked obvious chemosensory

defects (Supplementary Fig. S5; Extended Text 1) and continued to arrest as dauers on 5mM 8-

Bromo-cGMP, which modestly rescues *daf-11*-associated dauer formation(3, 43) (Supplementary

Fig. 6a). Therefore, to identify signal transduction pathways through which the loss of ILC-17.1

signaling controlled the dauer decision, we examined its genetic interactions with *daf-16, daf-5*,

and DA signaling.

A *daf-16* loss of function mutation*, mu86*(44)*,* completely suppressed dauer formation in animals

lacking ILC-17.1, indicating that activation of DAF-16 was one mechanism responsible for their

dauer arrest (Fig. 2a). The activation of DAF-16 in animals lacking ILC-17.1 could be quantified

by an increase in the proportion of larvae with DAF-16::GFP(45) positive intestinal nuclei even at

20°C (Fig. 2b-d), and the upregulation of DAF-16 target genes(46, 47) both at 20°C

(Supplementary Fig. S6b) and 25°C (Fig.2e). DAF-16 activation could be suppressed by re-

expressing ILC-17.1 in *ilc-17.1* deletion mutants under its endogenous promoter, or ectopically,

under the muscle-specific promoter (Fig.2e). Surprisingly, a loss of function mutation in *daf-5*,

e1386(48) also completely suppressed the dauer arrest of *ilc-17.1* mutant larvae (Fig. 2f), and

exposing *ilc-17.1* deficient larvae to 50 nM exogenous Δ7-dafachronic acid (42), partially but

significantly suppressed their dauer arrest (Fig 2g). The activation of DAF-16/FOXO and DAF-

3/SMAD-DAF-5/Ski by the loss of ILC-17.1 was not simply because *ilc-17.1* deleted larvae were

deficient in the expression of insulin signaling and TGFβ/ DAF-7 signaling pathway components,

as determined by expression levels of the signaling pathway components and transcriptional

reporters [Supplementary Fig S7; Datasets S7, S8, see Extended Text 2 for details]. The dauer

arrest of *daf-2* (*e1370*)(49)*,* could not be rescued by ILC-17.1 overexpression, suggesting that

ILC-17.1 did not act genetically downstream of *daf-2* (Supplementary Fig. S8a). Thus, it appeared

that ILC-17.1 acted upstream of both DAF-16/FOXO and DAF-3/SMAD-DAF-5/Ski (and likely,

DAF-9/DAF-12), but not downstream of DAF-2, to modulate dauer entry.

This was curious, since DAF-16/FOXO and DAF-3/SMAD-DAF-5/Ski are thought to act

independently, and in parallel to modulate the *C. elegans* dauer decision(3, 5). Therefore, to

identify mechanism(s) that could activate both pathways in *ilc-17.1* deleted larvae, we conducted

RNAi knockdown of candidate genes known to interact with these dauer effectors (50-57), and

asked which, if any, also rescued the dauer entry of *ilc-17.1* larvae (Supplementary Fig. S8b). We

considered only the positive hits, due to the variable penetrance of RNAi. Amongst the positive

candidates, we found most interesting, *cep-1*, the *C. elegans* ortholog of p53(58, 59), since p53-

family of proteins restrain cell cycle progression and alter metabolism, both cardinal features of

dauer entry. Indeed, a deletion in *cep-1*, *gk138*, rescued the dauer arrest of *ilc-17.1* deletion

mutants and nearly all (98%) of *cep-1;ilc-17.1* double mutant larvae grew into reproductive adults

(Fig 2h-j), suggesting that CEP-1/p53 was also responsible for the dauer phenotype of *ilc-17.1*

mutants, and was activated.

In mammalian cells, p53 activation occurs through an increase in p53 protein levels due to its

escape from constitutive degradation by the E3 ubiquitin ligase MDM2(18, 20, 60). Although the

C. elegans genome lacks MDM2 orthologs, CEP-1/p53 activation through translational and

posttranslational modifications has been reported (61, 62). We therefore used Western analysis

of FLAG-tagged endogenous *C.* elegans CEP-1/p53 to test whether CEP-1/p53 was activated in

ilc-17.1 mutant larvae, as implied by the rescue. This was the case: in *ilc-17.1* deleted larvae,

CEP-1::FLAG levels increased by 2-fold, levels similar to that seen upon gamma irradiation, which

also activates CEP-1/p53, and was used as a positive control (Fig 3a) (63, 64). Accordingly,

overexpressing CEP-1 alone, even to a modest 1.5-fold level over wild type (see Supplementary

Fig. S9a for *cep-1 o/e* mRNA levels), was sufficient to arrest growth and promote an almost

completely penetrant dauer phenotype (Fig. 3b-d). CEP-1 overexpression was achieved by

crossing out the *cep-1 lg12501* deletion mutation from a widely used transgenic strain expressing

functional, fluorescently tagged, CEP-1, CEP-1::GFP, under its own promoter (61, 65, 66). In the

cep-1(*lg12501*) strain, CEP-1::GFP is the only source of CEP-1/p53, rescues *cep-1* (*lg12501*)

apoptosis defects and is expressed at half the levels of wild type (Supplementary Fig. S9a; *cep-*

1 mRNA levels). CEP-1::GFP did not induce dauer arrest in the *cep-1, lg12501* deletion

background (Fig. 3b), indicating that *cep-1* expression levels, and not the GFP tag, was

responsible for the dauer arrest of CEP-1::GFP overexpressing larvae . The overexpression of

CEP-1/p53 phenocopied the *ilc-17.1* deletion, not only causing all larvae to arrest as dauers at

25°C, but also prompting transient dauer entry at 20°C, as assessed by SDS-resistance

(Supplementary Fig. S9b). RNA-seq analysis showed that genes differentially expressed in CEP-

1/p53 overexpressing larvae *en route* to their dauer arrest, significantly overlapped with those

expressed in larvae lacking ILC-17.1 (Fig. 3e, padj.< 0.05; Datasets S9, S10). CEP-1/p53

overexpressing larvae also upregulated dauer-specific collagens (Supplementary Fig. S9c;

Dataset S4), downregulated anabolic pathways (Supplementary Fig. S9d), and upregulated

catabolic pathways (Supplementary Fig. S9e). In addition, between 15 hours to 32 hours post-

hatching at 25°C, CEP-1/p53 overexpressing larvae and *ilc-17.1* deletion mutants showed a

remarkably constant gene expression profile, and only 340 and 34 genes respectively changed

expression (p<0.05), compared to the > 10,000 genes that were either upregulated or

downregulated in wild-type larvae and *cep-1;ilc-17.1* double mutant larvae that *en route* to

becoming reproductive adults (PCA analysis; Supplementary Fig. S9f; Dataset S11). The

upregulation of known CEP-1/p53 targets (63, 64, 67, 68), the BH3-only proteins *egl-1* and *ced-*

13, in the *ilc-17.1* deletion mutants, in a *cep-1*-dependent manner, at both 20°C and 25°C, further

confirmed CEP-1/p53 activation in the absence of ILC-17.1 (Fig 3f and Supplementary Fig. S10a).

The upregulation of CEP-1/p53-targets in *ilc-17.1* deletion mutants could be suppressed by re-

expressing ILC-17.1 under its endogenous-, or muscle-specific promoters (Fig 3f; Supplementary

Fig. S10a). In addition, Chromatin Immunoprecipitation followed by quantitative PCR (ChIP-

qPCR) using FLAG tagged *cep-1* animals showed that the loss of *ilc-17.1* increased CEP-1/p53

binding at promoter regions of *egl-1* and *ced-13*, and the increased occupancy was abrogated

upon re-expressing ILC-17.1 (Fig. 3g, h).

Like in the ILC-17.1 deficient animals, the dauer arrest of larvae overexpressing CEP-1 was

dependent on DAF-16, DAF-5 and the steroid hormone pathway: downregulating *daf-16*

expression by RNAi (Fig. 4a), crossing CEP-1/p53 overexpressing larvae into *daf-5*, *e1386*, or

treatment with 50nM exogenous Δ7-dafachronic acid, all suppressed their dauer arrest (Fig. 4b).

In accordance, DAF-16 target genes were also upregulated in larvae overexpressing CEP-1/p53

at both 25°C (Fig 4c) and 20°C (Supplementary Fig. S10b). Differentially expressed genes in

CEP-1/53 overexpressing larvae overlapped with published gene expression profiles of *daf-2*

(e1370) and active DAF-16 (Supplementary Fig. S10 c,d; Datasets S12, S13). In addition, and

most convincing, the upregulation of *daf-16* target genes in *ilc-71.1* deletion mutant larvae was

cep-1 dependent at both 25°C and 20°C (Fig 4c; Supplementary Fig. S10b). CEP-1/p53

activation-induced dauer entry appeared to be somewhat specific to reduced ILC-17.1 signaling,

as the dauer arrest of *daf-2*(*e1370*) larvae that occurred due to reduced insulin signaling did not

depend on *cep-1* (Supplementary Fig. S10e). Moreover, in agreement with previous reports(69,

70), *cep-1* was not required for dauer induction at high temperatures as *cep-1* (*gk138*) larvae

could enter dauer at 27°C just like wild-type animals (Supplementary Fig. S10f). Taken together,

these results showed that ILC-17.1 normally acted to represses CEP-1/p53 transcriptional activity.

Upon loss of ILC-17.1 signaling, CEP-1/p53 was activated, in turn activated DAF-16/FOXO (and

perhaps DAF-3/SMAD-DAF-5/Ski and DAF-12) to trigger the dauer arrest of *ilc-17.1* deletion

mutants. However, the ILC-17.1/CEP-1 dauer axis appeared independent of the insulin-like

receptor, *daf-2*, *per se*.

CEP-1/p53 directly or indirectly controls cell cycle progression.

A conserved function of the p53-family of proteins is to restrain cell cycle progression. In *C.*

elegans, most cell divisions are completed during embryogenesis, but a subset of somatic and

germ line cells divide and differentiate post-embryonically, and these cells arrest during dauer

entry(71-76) (77, 78). (79-86). We therefore tested whether CEP-1/p53 activation upon loss of

ILC-17.1 was participating in the arrest of cell cycle progression during postembryonic

development. Indeed, *ilc-17.1* deleted larvae upregulated mRNA levels of cell cycle inhibitors *cki-*

1, one of the two p21 homologs, and *phg-1,* the *C. elegans* homologue of Growth arrest-specific

1 (Gas1) (Fig 4d). These are known to regulated by CEP-1/p53 (87). *phg-1,* but not *cki-1,* was a

direct target of CEP-1/p53, in *ilc-17.1* deletion mutants, which displayed increased CEP-1/p53

occupancy at the *phg-1* promoter (Fig. 4e; Supplementary Fig. S11a). Again, as with the other

CEP-1/p53 targets, the increased expression of *cki-1* and *phg-1,* and the increased occupancy at

the *phg-1* promoter was restored to wild-type levels upon re-expressing ILC-17.1 (Fig. 4d, e).

Surprisingly, downregulation of *phg-1* and *cki-1* by RNAi modestly, but significantly, rescued

dauer arrest in *ilc-17.1* deletion mutants and CEP-1/p53 overexpressing larvae and allowed a

small number of larvae to develop into adults (Supplementary Fig. S11b). Crossing *ilc-17.1*

deletion mutants into *phg-1* deletion mutants, *ok2741* also resulted in a rescue and ~40% escaped

dauer arrest and grew into reproductive adults (Fig. 4f, g). In addition, a proportion of *ilc-17.1*

deletion mutant and CEP-1/p53 overexpressing larvae that appeared morphologically dauer*,*

displayed modest but significant non-dauer physiological traits on *phg-1* and *cki-1* RNAi such as

increased rates of sporadic pumping (Supplementary Fig. S11c; wild-type L2 were used as

controls), suggesting there may also occur a wider, albeit incomplete, dauer rescue in some

tissues. The dauer arrest of *daf-2* mutant larvae which did not depend on *cep-1,* was also not

rescued upon downregulating *phg-1* or *cki-1*, nor were the pumping rates of *daf-2* dauers altered

(Supplementary Fig. S11 b,c). Although we cannot distinguish at this time, whether the

downregulation of the cell cycle inhibitors allowed larvae to exit dauer, or suppressed dauer entry

and complete arrest, these data showed that loss of ILC-17.1 signaling or overexpressing CEP-

1/p53 upregulated CEP-1/p53-dependent cell cycle inhibitors, and this increase appeared to be

one mechanism responsible, at least in part, for the dauer arrest.

ILC-17.1 links glucose metabolism to CEP-1/p53 activity.

Mammalian p53 plays a central roles in energy metabolism and, in turn, can be activated by

energy deprivation or limited glucose, through signaling by AMP-activated protein kinase (AMPK)

or Mammalian target of rapamycin (mTOR) pathways (88, 89). Therefore, the responsiveness of

ILC-17.1 to food signals suggested the intriguing possibility that the loss of ILC-17.1 signaling

activated CEP-1/p53 because of energy deprivation, and this could link nutrient availability to

metabolism and cell cycle progression. AMPK did not appear to be activated in *ilc-17.1* deleted

animals (Supplementary Fig. S12a), nor was mTOR activity obviously reduced (Supplementary

Fig. S12b). However, ILC-17.1 signaling did appear to link glucose utilization to developmental

progression, since downregulating *fgt-1,* the main Glucose transporter (GLUT) responsible for

glucose absorption in *C. elegans*(90), decreased the extent of dauer-rescue conferred by re-

expressing ILC-17.1 in *ilc-17.1* mutant larvae (Fig. 5a), and increased the numbers of *ilc-17.1*

deletion mutant larvae that arrested as dauers at 20°C (Fig. 5b). Conversely, extra glucose(91)

suppressed the dauer arrest of approximately 30% *ilc-17.1* deficient larvae (Fig. 5c;

Supplementary Fig. S12c), suggesting that the normal amounts of glucose available in the diets

of *C. elegans* larvae was insufficient for *ilc-17.1* larvae to develop into adults. Consistently,

decreasing glucose import through *fgt-1* RNAi once again, lowered the percentage of larvae that

were rescued by the extra glucose (Supplementary Fig. S12d), and no rescue was observed on

the non-hydrolysable glucose analog 2-Deoxy-d-glucose (2-DOG; Supplementary Fig. S12e)

which cannot undergo glycolysis and does not enter the metabolic pathway. The same

concentrations of glucose could not rescue *daf-*2 larvae that arrested as dauers (Fig 5c). We ruled

out non-specific effects of glucose rescue by testing the role of increased ROS or other

supplements (Supplementary Fig S12e-f; see Supporting Information; Extended Text 3 for

details). Downregulating *fgt-1* in wild-type larvae, while not sufficient to trigger dauer arrest,

modestly increased the expression of CEP-1/p53 target *egl-1* (but not *ced-13*; Supplementary

Fig. S12g). Thus, these data supported the possibility that the activation of CEP-1/p53 upon the

loss of ILC-17.1 could, at least in part, occur due an impairment in the *ilc-17.1* deleted larvae's

ability to utilize glucose.

Glucose supplementation also rescued dauer arrest of CEP-1/p53 overexpressing larvae (Fig 5c;

Supplementary Fig. S10c), arguing that decreased glucose intake in the absence of ILC-17.1 was

not a consequence of CEP-1/p53 activation, but instead acted logically upstream of CEP-1/p53.

In agreement, extra glucose suppressed the increased expression of *phg-1* the direct target of

CEP-1/p53, and decreased DAF-16/FOXO activation (Fig.5d). Surprisingly, not only did CEP-

1/p53 appear to be activated by the inability of *ilc-17.1* to utilize glucose normally, but CEP-1/p53

activity, in turn decreased the expression levels of key enzymes involved in glucose

metabolism(92): phosphofructokinase-1.2 (*pfk-1.2*), the rate limiting enzyme in glycolysis, and

cytochrome *c* (*cyc-2.2*), the complex IV subunit of the mitochondrial electron transport chain

responsible. This was visible in the RNA-seq data (Supplementary Figure S13 a-f; Dataset S14)

and confirmed by qRT-PCR (Supplementary Figure S13g, Fig. 5e). Moreover, although the

downregulation of *pfk-1.2* or *cyc-2.2* alone was not sufficient to induce dauer in wild-type animals,

RNAi knockdown of *cyc-2.2* in *ilc-17.1* deleted larvae increased the percentage of dauers under

optimal conditions of 20°C, suggesting that CEP-1/p53-dependent decrease of *cyc-2.2* could

feedback onto *ilc-17.1* loss to increase dauer propensity (Supplementary Figure S13h). These

data, together, suggested that the loss of ILC-17.1 impaired glucose utilization and this activated

CEP-1/p53, which, then further limited glucose utilization by downregulating genes important for

glycolysis and OXPHOS. Thus, ILC-17 secretion from amphid neurons that occurred in response

to food availability appeared to link cell fate decisions with energy metabolism through CEP-1/p53.

ILC-17.1 suppresses CEP-1/p53 in *C. elegans* and human epithelial cells.

Our data pointed towards a model whereby ILC-17.1 signaling suppressed CEP-1/p53. Therefore,

we tested this directly. Indeed, overexpressing ILC-17.1 in animals also overexpressing CEP-

1/p53 inhibited their dauer arrest (Fig. 6a). In addition, since the most-accepted and canonical

function of *C.elegans* CEP-1/p53 is in triggering apoptosis in the adult germ line in response to

DNA-damage, we also examined whether ILC-17.1 repressed CEP-1/p53's function in apoptosis.

As has been previously shown(67), the loss of CEP-1/p53 in *cep-1 (gk138)* adults has negligible

effects on physiological apoptosis, but suppresses the increased apoptosis that occurs in

response to gamma irradiation (Fig. 6b). CEP-1/p53 overexpression, surprisingly, caused a

significant increase in physiological apoptosis, and a marked increase in irradiation-induced

apoptosis, both of which could be suppressed by also overexpressing ILC-17.1 (Fig 6b).

Overexpressing *ilc-17.1* in a wild-type background also decreased physiological and irradiation-

induced apoptosis, but this effect was variable and did not reach significance (average nos. of

apoptotic cells in non-irradiated N2 v ILC-17.1 overexpressing animals were 3.56 ± 1.3 and 2.53

± 1.1 cells, and upon irradiation, increased to 7.1 ± 1.8 in N2, and 5.72 ± 2.2 in IL-17

overexpressing animals). For reasons that remain to be understood, ilc-*17.1* deletion did not alter

apoptosis in the adult germ line, perhaps reflecting a different function post-development. IL-17

could also modestly repress p53, autonomously, in mammalian cells (Supplementary Fig S14a-

b; see Extended Text 4 for details). Together, these data suggest that the inhibition of CEP-

1/p53's activity could be a conserved function of IL-17s.

Discussion

Here we show roles for the interleukin 17 (IL-17) family of cytokines and p53 in the development

of an invertebrate species, *C. elegans*. Our data support a model whereby ILC-17.1 signaling of

food availability by amphid neurons ensures the continuous growth of larvae into reproductive

adults under favorable conditions through suppression of CEP-1/p53. IL-17s play broad-ranging

immunometabolic roles in mammals and are one of the most conserved proinflammatory

cytokines among animal phyla. Thus, their ancestral role in signaling nutrient availability as in *C.*

elegans may be broadly conserved. Our data also reveal that reduced ILC-17.1 signaling,

expected to occur when food is scarce, activates CEP-1/p53, to trigger dauer arrest through the

well characterized dauer activating pathways, DAF-16/FOXO, DAF-3/SMAD-DAF-5/Ski and also,

perhaps steroid hormone signaling. In its role in promoting dauer arrest in *C. elegans*, CEP-1/p53

inhibits cell cycle progression, and modulates metabolic flux by directly or indirectly controlling the

levels of phosphofructokinase (*pfk*-1) and cytochrome C (*cyc-2.2*). Notably, these are also

mechanisms by which p53 restrains tumorigenesis. In mammals too, uncontrolled p53 activity is

associated with a developmental syndrome through its effects on cell cycle progression, apoptosis

and the migration of neural crest cells(25). We therefore cautiously propose that the ancestral

roles of the p53 gene-family in modulating development could have the driving force in their

evolution.

While, there remain several puzzling aspects associated with this study, our data indicate that

there may exist a previously undiscovered *C. elegans* dauer pathway. The dauers formed by *ilc-*

17.1 deletion, or the modest 1.5X increase in CEP-1/p53 expression, display all the cardinal

morphological and physiological features of dauers, including SDS-resistance, decreased

pumping rates, presence of alae, changes in collagens, upregulation of catabolic and

downregulation of anabolic genes, and the ability to remain arrested for days to weeks as dauers.

Nevertheless, they also differ in some respects from the well-studied dauers formed through

decreased insulin signaling (*daf-2*), and other pathways, in that, unlike previously studied dauers,

a modest, but significant percentage of *ilc-17.1* dauers larvae bypass or are rescued from dauer

upon downregulating cell cycle inhibitors such as *phg-1*, or when fed extra glucose. This suggests

that there may exist different 'types' of dauer larvae. The discovery of new *C. elegans* dauer

pathway genes is surprising given the extensive genetic screens that have been conducted(3, 5,

30-32). However, genes that require a complete deletion to confer a dauer phenotype, or genes

that control development through complex and antagonistic tissue specific effects, as possible for

ilcr-2, could have been missed. In this regard, two other deletions of the *ilc-17.1* exist in the

community (*tm5218 and tm5124*). These do not arrest as dauers, but are also not null alleles and

express exons 1 and 2 of *ilc-17.1* transcript (Supplementary Figure S14c). However, the *tm5218*

deletion removes the predicted beta strands required for the canonical cysteine knot fold of IL-

17s and might have arguably been expected to be result in the loss of ILC-17.1 signaling

capability, mimic *ilc-17.1* deletion mutants, and arrest as dauers. Although this is not the case,

and all *tm5218* homozygotes escape dauer arrest, a variable, but significant percentage of trans-

heterozygotes for *ilc-17.1(tm5218)* and *ilc-17.1*(*syb5296*) larvae arrest as dauers, as confirmed

by PCR genotyping, indicating non-complementation (Supplementary Figure S14d; results from

one experiment; dauer arrest varied between 0-75% of F1 trans-heterozygotes; n>10

experiments). This observation adds confidence to the role of *ilc-17.1* in dauer, but also reinforces

our lack of understanding of the nature and stoichiometry of the IL-17 homo/heterodimers and IL-

17-ILCR-2 signaling assemblies in *C. elegans*.

We hypothesize that ILC-17.1 is secreted upon sensory neuronal activity to control CEP-1/p53

activity, but this remains to be shown, and the neuronal circuits identified(93). Nutrient scarcity

has shaped much of evolution, and the ability of cells and organisms to sense nutrient availability

and prepare in anticipation to pause cell cycle progression and growth and maintain a quiescent

state until resources are optimal, has unquestionable selective advantages. For *C. elegans*, like

for most organisms, the availability of food is not guaranteed. Neuronal ILC-17.1 signaling

appears to be one mechanism which allows the animal to match the cell fate programs and

metabolic requirements of the developing larvae with resource availability. Neurons also control

dauer entry though TGFβ and insulin signaling. In addition, other stress-responsive

transcriptional programs that can be activated autonomously by cells, are also controlled through

neuronal signaling in *C. elegans*, allowing the nervous system to coordinate tissue-specific

transcriptional and epigenetic responses with organismal physiology and behavior(94-97). The

extent to which IL-17s function similarly in mammals remains to be understood (98, 99).

Materials and Methods: Descriptions of strains and methods are included in Supporting

Information (SI), Extended Methods. Strains will be available upon request, after publication.

The data discussed in this publication have been deposited in NCBI's Gene Expression

Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number

GSE218596, , https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE218596 and

GSE229132, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE229132

Figure 1: ILC-17.1 signaling of food availability by larval amphid neurons modulates dauer arrest.

(a), Schematic of experiment. For each experiment, independent samples of 10 day-one adults of each strain laid eggs for two-four hours at 20°C on OP50 lawns. Adults were removed, embryos transferred to 25°C., larval phenotype scored after approximately 48 hr., and categorized as dauers or stage 4 larvae (L4) and/or young adults. SDS-resistance was used to confirm dauers. Extent of crowding on plates was comparable (Representative average numbers of embryos/plates are 64, 68, 56, 46 and 65 for wild type (N2), *ilc-17.1(syb5296)* X, *ilc-17.1(syb5297)* X, *ilc-17.1(syb5296)* rescued with *ilc-17.1p::ilc-17.1*, and *ilc-17.1(syb5296)* rescued with *unc-54p::ilc-17.1* respectively). *ilc-17.1 rescued (ilc-17.1p)* are *ilc-17.1* deletion mutants expressing extrachromosomal *ilc-17.1* cDNA driven by *ilc-17.1* promoter. *ilc-17.1 rescued (unc-54p)* are *ilc-17.1* deletion mutants expressing extrachromosomal *ilc-17.1* cDNA driven by *unc-54* promoter. Pearson's Chi-squared test with Yates' continuity correction was used to compare samples in manuscript, unless otherwise stated. Chi-squared, df and p values for the whole experiment and p values for pair-wise comparisons are reported. ***p < 0.001, **p < 0.01, *p < 0.05 and ns, not significant. **(b),** Percentage larvae that arrest as dauers, (*n*=3-12 experiments; Chi-squared = 2359.6, df = 4, p-value < 2.2e-16.). (**c**, **d**). Representative micrographs 48 hours post-hatching at 25°C: **(c),** wild type (N2) are L4s, **(d),** *ilc-17.1(syb5296)* are dauer. Scale bar, 1 mm. **(e)**. Percentage dauers amongst wild type (N2), and *ilc-17.1* mutants on control (L4440) and *ilcr-2* RNAi, (n=3-10 experiments. Chi-squared = 1815.1, df = 7, p-value < 2.2e-16.). **(f),** Schematic of AID experiment to degrade ILCR-2. **(g),** Percentage dauers following tissue specific degradation of ILCR-2. X-axis: tissue specific TIR1 expression, (n=4-6 experiments; Chi-squared = 335.56, df =9 , p-value <2.2e-16). **(h).** Schematic of experiment to localize *ilc-17.1* mRNA and ILC-17.1 protein in the presence and absence of food (OP50). Embryos hatched at 20°C and imaged after 24-36 hours (L1 stage larvae): **(i, k),** Representative micrographs of z-section of pharyngeal region of larvae showing mCherry as

proxy for *ilc-17.1* mRNA expression in amphid neurons**. (j, l),** z-section projection showing

immunolocalization of ILC-17.1::HA protein. **(i, j)** larvae in absence of food, and **(k, l),** presence

of food. **(m, n),** Controls (N2) that do not express HA or mCherry to indicate specificity of the

fluorescence signal. (n>3 experiments, 4-5 larvae each). Scale bar, 5µm. (**o),** KEGG

enrichments associated with differentially downregulated genes, and (**p**), differentially

upregulated genes in *ilc-17.1* mutant larvae. p.adjust <0.05. RNA-seq on 32-36 hr. larvae. (**q),**

Heatmap depicting expression levels ($\log_2$ normalized counts) of the major dauer-specific

collagens in L2 wild-type (N2) larvae *en route* to adult development, *ilc-17.1* deletion mutants *en*

route to dauer entry and *ilc-17.1* deletion mutants rescued from dauer with *unc-54p::ilc-17.1.*

Bars show mean ± S.E.M. Individual data points in the bar graphs in **b** and **e, g** represent the %

dauers/experiment, and the bar graph depicts mean of these percentages. ***$p < 0.001$,

**$p < 0.01$, *$p < 0.05$ and ns, not significant

Figure 2: Reduced ILC-17.1 signaling acts through DAF-16/FOXO, DAF-3/SMAD-DAF-5/Ski complex, steroid hormone signaling and CEP-1/p53 to control dauer arrest.

(a), Percent dauers. X-axis: genotype. (n=4-8 experiments, Chi-squared = 497.65, df = 1, p-value < 2.2e-16). **(b),** Percent 36 hrs larvae, grown at 20°C showing nuclear DAF-16::GFP. n=3 experiments with 10-15 larvae each. Each data point represents average no. of larvae with nuclear DAF-16::GFP/experiment, (unpaired t-test). Note: experiments were conducted at 20°C, since DAF-16::GFP localized constitutively in intestinal nuclei even in wild-type larvae at 25°C. **(c, d),** representative micrographs of DAF-16::GFP (boxed) in wild type and *ilc-17.1* deletion mutant larvae. Scale bar, 5μm. **(e),** Average *sod-3, mtl-1, and lys-7* mRNA levels in larvae 32-36 hr. post-hatching at 25°C. mRNA levels are relative to *pmp-3* and normalized to wild type (N2) values. n=4-10 experiments, (unpaired t-test). **(f),** Percent dauers. X-axis: genotype. (n=3-5 experiments, Chi-squared = 787.3, df = 3, p-value < 2.2e-16). **(g),** Percent dauers in *ilc-17.1* mutants on control (H_2O) and exogenous 50nM Δ7-dafachronic acid (DA), (n=3-5 experiments, Chi-squared = 784.32, df = 3, p-value < 2.2e-16). **(h),** Percent dauers, X-axis: genotype (n=3-5 experiments, Chi-squared = 1029.2, df = 3, p-value < 2.2e-16). **(i, j),** Representative micrographs of **i,** *ilc-17.1* deleted larvae arrested as dauers, and j**,** *ilc-17.1;cep-1* that grew to L4s, 48 hr. post-hatching at 25°C. Scale bar, 1 mm. Bars show the mean ± S.E.M. Individual data points in bar graphs in **a, f-h,** represent the average % dauers/experiment. ***p < 0.001, **p < 0.01, *p < 0.05 and ns, not significant

Figure 3: CEP-1/p53 is activated by reduced ILC-17.1 signaling.

(a), Top: Representative Western blot showing CEP-1::FLAG and tubulin. Bands on western correspond to numbers in data bars. *cep-1* RNAi used for specificity. Samples constitute 32-36 hr. larvae grown at 25°C, except for positive control, irradiated sample (#4; adults). **Bottom**: Average CEP-1 levels quantified relative to tubulin and normalized to control (Ctrl; CEP-1::FLAG in wild-type background). n=4 experiments. (unpaired t-test). **(b),** Percent dauers. X-axis: genotype. (n=3-4 experiments, Chi-squared = 569.35, df = 2, p-value < 2.2e-16). mRNA expression levels in *cep-1* OE and *cep-1 (lg12501)*; CEP-1::GFP were ~1.5X and ~0.5X wild-type levels, respectively, see **Supplementary Fig. S9a**. **(c, d),** Representative micrographs 48 hrs. post-hatching at 25°C, of **c,** CEP-1/p53 overexpressing larvae arrested as dauers and **d,** *cep-1 (lg12501)*; CEP-1::GFP L4s. Scale bar, 1 mm. **(e),** Venn diagram depicting overlap between differentially expressed genes (p<0.05) in *ilc-17.1* deletion mutants and CEP-1/p53 overexpressing larvae, 32-36 hr. post-hatching at 25°C. p<0.0; hypergeometric test. **(f),** Average *egl-1* and *ced-13* mRNA levels in 32-36 hr. larvae grown at 25°C. n=6-7 experiments. mRNA levels relative to *pmp-3* and normalized to wild-type (N2) values. (unpaired t-test). **(g, h),** CEP-1 occupancy (percent input; CEP-1::FLAG was immunoprecipitated with anti-FLAG antibody) at the promoter proximal regions of **g,** *egl-1* and **h,** *ced-13* in 32-36 hr. larvae grown at 25°C, (**Top, schematic**)*. X-axis: genotype. n=4 experiments. (unpaired t-test). **(a, g, h)**, endogenous *cep-1* was FLAG tagged at its C-terminus using CRISPR/Cas9, crossed into backgrounds noted and probed with anti-FLAG antibody. Bars show the mean ± S.E.M. Individual points in bar graphs in **b** represent the % dauers/experiment. ***p < 0.001, **p < 0.01, *p < 0.05 and ns, not significant.

Figure 4. CEP-1/p53 acts through DAF-16/FOXO, DAF-3/SMAD-DAF-5/Ski complex and cell cycle inhibitors to control dauer entry.

(a), Percent dauers. X-axis: genotype and RNAi treatment: Ctrl, L4440 or *daf-16*. (n=3-4 experiments, Chi-squared = 494.22, df = 3, p-value < 2.2e-16). **(b),** Percent dauers. X-axis: genotype and treatment: water (control) and 50nM Δ7-dafachronic acid (DA). (n=3-4 experiments, Chi-squared = 982.66, df = 5, p-value < 2.2e-16). **(c),** Average *sod-3, mtl-1, and lys-7* mRNA levels in larvae 32-36 hr. post-hatching at 25°C. n=4-10 experiments. (unpaired t-test). **(d)**, Average *cki-1* and *phg-1* mRNA levels in 32-36 hr. larvae grown at 25°C. **(c, d)** mRNA levels were determined relative to *pmp-3* and normalized to wild-type (N2) values. n=4-6 experiments. *p < 0.05. (unpaired t-test). **(e),** CEP-1 occupancy (percent input) in 32-36 hr. larvae grown at 25°C, at the promoter proximal region of *phg-1* (**Top,** schematic)*.* X-axis: genotype. n=4 experiments. (unpaired t-test). **(f),** Percent dauers*.* X-axis: genotype. (n=6 experiments, Chi-squared = 826.95, df = 3, p-value< 2.2e-16). **(g),** Representative micrograph 48 hrs. post-hatching at 25°C of *ilc-17.1;phg-1* double mutants, showing dauers (arrows) and L4s. Scale bar, 1 mm**. (a**, **b**, **f),** Bar graphs: bars show the mean ± S.E.M, and individual points represent the % dauers/experiment. ***p < 0.001, **p < 0.01, *p < 0.05 and ns, not significant.

.

Figure 5. Impaired glucose utilization in ILC-17.1 deficient larvae activates CEP-1/p53

and alters the expression of OXPHOS genes.

(a), Top: Schematic of experimental design. **Right**: Percent dauers. X-axis: genotype. Larve

treated with control (L4440) and *fgt-1* RNAi. (n= 5 experiments, Chi-squared = 1817.1, df = 5, p-

value < 2.2e-16). **(b), Bottom**: Schematic of experimental design. **Right**: Percent SDS (1%)-

resistant dauers at 48 and 72 hrs. post-hatching and grown at optimal conditions of 20°C. X-

axis: genotype. Larve treated with control (L4440) and *fgt-1* RNAi. (n= 3 experiments, Chi-

squared = 206.82, df = 7, p-value < 2.2e-16). **(c), Top**: Schematic of experimental design.

Bottom: Percent dauers. X-axis: genotype and treatment: Control (H_2O) and 50mM glucose.

(n= 3-6 experiments, Chi-squared = 2882.3, df = 5, p-value < 2.2e-16). **(d),** Average *phg-1, sod-*

3 and mtl-1 mRNA levels in 32-36 hr. larvae that arrest as dauers (on H_2O, control) and larvae

that bypass dauer (50mM glucose) at 25°C. mRNA levels are relative to *pmp-3* and normalized

to wild-type (N2) values. n=3 experiments. (unpaired t-test). **(e),** Average *cyc-2.2* mRNA levels

in 32-36 hr. larvae. mRNA levels are relative to *pmp-3* and normalized to the wild-type (N2)

values. n=4-6 experiments.. (unpaired t-test). Bars show the mean ± S.E.M. Individual points in

the bar graphs in **a, b, c** represent the % dauers/experiment, ***p < 0.001, **p < 0.01, *p < 0.05,

ns, non-significant.

Figure 6: ILC-17.1 suppresses CEP-1/p53.

(a), Percent dauers. X-axis: genotype. (n=4 experiments, Chi-squared = 1245.4, df = 2, p-value < 2.2e-16). **(b), Top:** Schematic of germline-specific apoptosis (apoptotic cells in red) scored with Acridine Orange. **Bottom:** Average numbers of apoptotic cells in day-two adult animals under control, non-irradiated conditions, and upon irradiation with 75 Gy (day-one adults were irradiated). n= 3 experiments, and 12 gonad arms/experiment. (analysis of variance (ANOVA) with Tukey's correction, df=13). Note: p values between N2 vs *ilc-17.1* OE (*unc-54p*), non-irradiated and irradiated are p=0.0192 and p=0.0623, if compared by themselves (unpaired t-test), but do not rise to significance when corrected for the multiple comparisons. Data in all graphs show mean ± S.E.M ***p < 0.001, **p < 0.01.

A**cknowledgements**

We thank the V.P. laboratory, Drs. Sarit Smolikove, Josep Comeron, Anna Malkova and Michael

Petrascheck for comments, Dr. Peter Ratcliffe, Oxford, for his generous gift of *CeHIF-1* antibody,

and Dr. Mario de Bono, Institute of Science and Technology Austria (ISTA) for *C. elegans* strains.

Nematode strains were provided by the Caenorhabditis Genetics Center (CGC) (funded by the

NIH Infrastructure Programs P40 OD010440). This work was supported by NIH R01 AG060616

(V.P.).

633   References

1. Golden JW & Riddle DL (1984) The Caenorhabditis elegans dauer larva: developmental
effects of pheromone, food, and temperature. *Dev Biol* 102(2):368-378.

2. Swanson MM & Riddle DL (1981) Critical periods in the development of the
Caenorhabditis elegans dauer larva. *Dev Biol* 84(1):27-40.

3. Hu PJ (2007) Dauer. *WormBook*:1-19.

4. Karp X (2018) Working with dauer larvae. *WormBook* 2018:1-19.

5. Fielenbach N & Antebi A (2008) C. elegans dauer formation and the molecular basis of
plasticity. *Genes Dev* 22(16):2149-2165.

6. Burnell AM, Houthoofd K, O'Hanlon K, & Vanfleteren JR (2005) Alternate metabolism
during the dauer stage of the nematode Caenorhabditis elegans. *Exp Gerontol*
40(11):850-856.

7. Rashid S, Wong C, & Roy R (2021) Developmental plasticity and the response to nutrient
stress in Caenorhabditis elegans. *Dev Biol* 475:265-276.

8. Cohen SM, Wrobel CJJ, Prakash SJ, Schroeder FC, & Sternberg PW (2022) Formation
and function of dauer ascarosides in the nematodes Caenorhabditis briggsae and
Caenorhabditis elegans. *G3 (Bethesda)* 12(3).

9. Braendle C, Milloz J, & Felix MA (2008) Mechanisms and evolution of environmental
responses in Caenorhabditis elegans. *Curr Top Dev Biol* 80:171-207.

10. Diaz SA & Viney M (2015) The evolution of plasticity of dauer larva developmental arrest
in the nematode Caenorhabditis elegans. *Ecol Evol* 5(6):1343-1353.

11. Ewald CY, Landis JN, Porter Abate J, Murphy CT, & Blackwell TK (2015) Dauer-
independent insulin/IGF-1-signalling implicates collagen remodelling in longevity. *Nature*
519(7541):97-101.

12.   Harvey SC, Shorto A, & Viney ME (2008) Quantitative genetic analysis of life-history traits

of Caenorhabditis elegans in stressful environments. *BMC Evol Biol* 8:15.

13.   Zhu J & Thompson CB (2019) Metabolic regulation of cell growth and proliferation. *Nat*

Rev Mol Cell Biol 20(7):436-450.

14.   Altan-Bonnet G & Mukherjee R (2019) Cytokine-mediated communication: a quantitative

appraisal of immune complexity. *Nat Rev Immunol* 19(4):205-217.

15.   Douglas A, Stevens B, & Lynch L (2023) Interleukin-17 as a key player in

neuroimmunometabolism. *Nat Metab* 5(7):1088-1100.

16.   Mills KHG (2022) IL-17 and IL-17-producing cells in protection versus pathology. *Nat Rev*

Immunol.

17.   Li X, Bechara R, Zhao J, McGeachy MJ, & Gaffen SL (2019) IL-17 receptor-based

signaling and implications for disease. *Nat Immunol* 20(12):1594-1602.

18.   Hall PA & Lane DP (1997) Tumor suppressors: a developing role for p53? *Curr Biol*

7(3):R144-147.

19.   Jain AK & Barton MC (2018) p53: emerging roles in stem cells, development and beyond.

Development 145(8).

20.   Levine AJ (2020) p53: 800 million years of evolution and 40 years of discovery. *Nat Rev*

Cancer 20(8):471-480.

21.   Rutkowski R, Hofmann K, & Gartner A (2010) Phylogeny and function of the invertebrate

p53 superfamily. *Cold Spring Harb Perspect Biol* 2(7):a001131.

22.   Pfister NT & Prives C (2017) Transcriptional Regulation by Wild-Type and Cancer-Related

Mutant Forms of p53. *Cold Spring Harb Perspect Med* 7(2).

23.   Lu WJ, Amatruda JF, & Abrams JM (2009) p53 ancestry: gazing through an evolutionary

lens. *Nat Rev Cancer* 9(10):758-762.

24. Bowen ME, Mulligan AS, Sorayya A, & Attardi LD (2021) Puma- and Caspase9-mediated

apoptosis is dispensable for p53-driven neural crest-based developmental defects. *Cell*

Death Differ 28(7):2083-2094.

25. Van Nostrand JL & Attardi LD (2014) Guilty as CHARGED: p53's expanding role in

disease. *Cell Cycle* 13(24):3798-3807.

26. Chen C*, et al.* (2017) IL-17 is a neuromodulator of Caenorhabditis elegans sensory

responses. *Nature* 542(7639):43-48.

27. Flynn SM*, et al.* (2020) MALT-1 mediates IL-17 neural signaling to regulate C. elegans

behavior, immunity and longevity. *Nat Commun* 11(1):2099.

28. Lillis M, Zaccardi NJ, & Heiman MG (2022) Axon-dendrite and apical-basolateral sorting

in a single neuron. *Genetics* 221(1).

29. Golden JW & Riddle DL (1984) A pheromone-induced developmental switch in

Caenorhabditis elegans: Temperature-sensitive mutants reveal a wild-type temperature-

dependent process. *Proc Natl Acad Sci U S A* 81(3):819-823.

30. Thomas JH, Birnby DA, & Vowels JJ (1993) Evidence for parallel processing of sensory

information controlling dauer formation in Caenorhabditis elegans. *Genetics* 134(4):1105-

1117.

31. Vowels JJ & Thomas JH (1992) Genetic analysis of chemosensory control of dauer

formation in Caenorhabditis elegans. *Genetics* 130(1):105-123.

32. Ailion M & Thomas JH (2003) Isolation and characterization of high-temperature-induced

Dauer formation mutants in Caenorhabditis elegans. *Genetics* 165(1):127-144.

33. Li W & Ou G (2016) The application of somatic CRISPR-Cas9 to conditional genome

editing in Caenorhabditis elegans. *Genesis* 54(4):170-181.

34. Paix A*, et al.* (2014) Scalable and versatile genome editing using linear DNAs with

microhomology to Cas9 Sites in Caenorhabditis elegans. *Genetics* 198(4):1347-1356.

35.   Xu S (2015) The application of CRISPR-Cas9 genome editing in Caenorhabditis elegans.

708   *J Genet Genomics* 42(8):413-421.

709   36.   Holt SJ (2006) Staying alive in adversity: transcriptome dynamics in the stress-resistant

710   dauer larva. *Funct Integr Genomics* 6(4):285-299.

711   37.   Cohen SM, Sun JJ, Schroeder FC, & Sternberg PW (2021) Transcriptional Response to

712   a Dauer-Inducing Ascaroside Cocktail in Late L1 in C. elegans. *MicroPubl Biol* 2021.

713   38.   Wang J & Kim SK (2003) Global analysis of dauer gene expression in Caenorhabditis

714   elegans. *Development* 130(8):1621-1634.

715   39.   Wirick MJ*, et al.* (2021) daf-16/FOXO blocks adult cell fate in Caenorhabditis elegans

716   dauer larvae via lin-41/TRIM71. *PLoS Genet* 17(11):e1009881.

717   40.   Kyani-Rogers T*, et al.* (2022) Developmental history modulates adult olfactory behavioral

718   preferences via regulation of chemoreceptor expression in Caenorhabditiselegans.

719   *Genetics* 222(3).

720   41.   Ow MC, Borziak K, Nichitean AM, Dorus S, & Hall SE (2018) Early experiences mediate

721   distinct adult gene expression and reproductive programs in Caenorhabditis elegans.

722   *PLoS Genet* 14(2):e1007219.

723   42.   Motola DL*, et al.* (2006) Identification of ligands for DAF-12 that govern dauer formation

724   and reproduction in C. elegans. *Cell* 124(6):1209-1223.

725   43.   Vowels JJ & Thomas JH (1994) Multiple chemosensory defects in daf-11 and daf-21

726   mutants of Caenorhabditis elegans. *Genetics* 138(2):303-316.

727   44.   Lin K, Dorman JB, Rodan A, & Kenyon C (1997) daf-16: An HNF-3/forkhead family

728   member that can function to double the life-span of Caenorhabditis elegans. *Science*

729   278(5341):1319-1322.

730   45.   Libina N, Berman JR, & Kenyon C (2003) Tissue-specific activities of C. elegans DAF-16

731   in the regulation of lifespan. *Cell* 115(4):489-502.

46.   Lee SS, Kennedy S, Tolonen AC, & Ruvkun G (2003) DAF-16 target genes that control

C. elegans life-span and metabolism. *Science* 300(5619):644-647.

47.   Kenyon C & Murphy CT (2006) Enrichment of regulatory motifs upstream of predicted

DAF-16 targets. *Nat Genet* 38(4):397-398; author reply 398.

48.   da Graca LS*, et al.* (2004) DAF-5 is a Ski oncoprotein homolog that functions in a neuronal

TGF beta pathway to regulate C. elegans dauer development. *Development* 131(2):435-

446.

49.   Gems D*, et al.* (1998) Two pleiotropic classes of daf-2 mutation affect larval arrest, adult

behavior, reproduction and longevity in Caenorhabditis elegans. *Genetics* 150(1):129-

155.

50.   Zecic A & Braeckman BP (2020) DAF-16/FoxO in Caenorhabditis elegans and Its Role in

Metabolic Remodeling. *Cells* 9(1).

51.   Oh SW*, et al.* (2005) JNK regulates lifespan in Caenorhabditis elegans by modulating

nuclear translocation of forkhead transcription factor/DAF-16. *Proc Natl Acad Sci U S A*

102(12):4494-4499.

52.   Greer EL*, et al.* (2007) An AMPK-FOXO pathway mediates longevity induced by a novel

method of dietary restriction in C. elegans. *Curr Biol* 17(19):1646-1656.

53.   Leiser SF, Begun A, & Kaeberlein M (2011) HIF-1 modulates longevity and healthspan in

a temperature-dependent manner. *Aging Cell* 10(2):318-326.

54.   Perrin AJ*, et al.* (2013) Noncanonical control of C. elegans germline apoptosis by the

insulin/IGF-1 and Ras/MAPK signaling pathways. *Cell Death Differ* 20(1):97-107.

55.   Gurkar AU*, et al.* (2018) Dysregulation of DAF-16/FOXO3A-mediated stress responses

accelerates oxidative DNA damage induced aging. *Redox Biol* 18:191-199.

56.   Baruah A*, et al.* (2014) CEP-1, the Caenorhabditis elegans p53 homolog, mediates

opposing longevity outcomes in mitochondrial electron transport chain mutants. *PLoS*

Genet 10(2):e1004097.

57.   Ewald CY, Castillo-Quan JI, & Blackwell TK (2018) Untangling Longevity, Dauer, and
759   Healthspan in Caenorhabditis elegans Insulin/IGF-1-Signalling. *Gerontology* 64(1):96-
760   104.

761   58.   Derry WB, Putzke AP, & Rothman JH (2001) Caenorhabditis elegans p53: role in
762   apoptosis, meiosis, and stress resistance. *Science* 294(5542):591-595.

763   59.   Schumacher B, Hofmann K, Boulton S, & Gartner A (2001) The C. elegans homolog of
764   the p53 tumor suppressor is required for DNA damage-induced apoptosis. *Curr Biol*
765   11(21):1722-1727.

766   60.   Prives C (1998) Signaling to p53: breaking the MDM2-p53 circuit. *Cell* 95(1):5-8.

767   61.   Schumacher B, *et al.* (2005) Translational repression of C. elegans p53 by GLD-1
768   regulates DNA damage-induced apoptosis. *Cell* 120(3):357-368.

769   62.   Sendoel A, Kohler I, Fellmann C, Lowe SW, & Hengartner MO (2010) HIF-1 antagonizes
770   p53-mediated apoptosis through a secreted neuronal tyrosinase. *Nature* 465(7298):577-
771   583.

772   63.   Gartner A, Boag PR, & Blackwell TK (2008) Germline survival and apoptosis.
773   *WormBook*:1-20.

774   64.   Schumacher B, *et al.* (2005) C. elegans ced-13 can promote apoptosis and is induced in
775   response to DNA damage. *Cell Death Differ* 12(2):153-161.

776   65.   Levi-Ferber M, *et al.* (2014) It's all in your mind: determining germ cell fate by neuronal
777   IRE-1 in C. elegans. *PLoS Genet* 10(10):e1004747.

778   66.   Hicks T, *et al.* (2022) R-loop-induced irreparable DNA damage evades checkpoint
779   detection in the C. elegans germline. *Nucleic Acids Res* 50(14):8041-8059.

780   67.   Greiss S, Schumacher B, Grandien K, Rothblatt J, & Gartner A (2008) Transcriptional
781   profiling in C. elegans suggests DNA damage dependent apoptosis as an ancient function
782   of the p53 family. *BMC Genomics* 9:334.

68.   Schertel C & Conradt B (2007) C. elegans orthologs of components of the RB tumor

suppressor complex have distinct pro-apoptotic functions. *Development* 134(20):3691-

3701.

69.   Arum O & Johnson TE (2007) Reduced expression of the Caenorhabditis elegans p53

ortholog cep-1 results in increased longevity. *J Gerontol A Biol Sci Med Sci* 62(9):951-

959.

70.   Lee CC*, et al.* (2014) Mutation of a Nopp140 gene dao-5 alters rDNA transcription and

increases germ cell apoptosis in C. elegans. *Cell Death Dis* 5:e1158.

71.   Sulston JE & Horvitz HR (1977) Post-embryonic cell lineages of the nematode,

Caenorhabditis elegans. *Dev Biol* 56(1):110-156.

72.   Sternberg PW (2005) Vulval development. *WormBook*:1-28.

73.   Horvitz HR & Sternberg PW (1982) Nematode postembryonic cell lineages. *J Nematol*

14(2):240-248.

74.   Chisholm AD & Hardin J (2005) Epidermal morphogenesis. *WormBook*:1-22.

75.   Herman MA (2006) Hermaphrodite cell-fate specification. *WormBook*:1-16.

76.   Costa M, Weir M, Coulson A, Sulston J, & Kenyon C (1988) Posterior pattern formation in

C. elegans involves position-specific expression of a gene containing a homeobox. *Cell*

55(5):747-756.

77.   Euling S & Ambros V (1996) Reversal of cell fate determination in Caenorhabditis elegans

vulval development. *Development* 122(8):2507-2515.

78.   Braendle C & Felix MA (2008) Plasticity and errors of a robust developmental system in

different environments. *Dev Cell* 15(5):714-724.

79.   Karp X & Greenwald I (2013) Control of cell-fate plasticity and maintenance of

multipotency by DAF-16/FoxO in quiescent Caenorhabditis elegans. *Proc Natl Acad Sci*

U S A 110(6):2181-2186.

80. Tenen CC & Greenwald I (2019) Cell Non-autonomous Function of daf-18/PTEN in the

Somatic Gonad Coordinates Somatic Gonad and Germline Development in C. elegans

Dauer Larvae. *Curr Biol* 29(6):1064-1072 e1068.

81. Hong Y, Roy R, & Ambros V (1998) Developmental regulation of a cyclin-dependent

kinase inhibitor controls postembryonic cell cycle progression in Caenorhabditis elegans.

Development 125(18):3585-3597.

82. Karp X & Ambros V (2012) Dauer larva quiescence alters the circuitry of microRNA

pathways regulating cell fate progression in C. elegans. *Development* 139(12):2177-2186.

83. O'Keeffe C & Greenwald I (2022) EGFR signal transduction is downregulated in C.

elegans vulval precursor cells during dauer diapause. *Development* 149(21).

84. Colella E, Li S, & Roy R (2016) Developmental and Cell Cycle Quiescence Is Mediated

by the Nuclear Hormone Receptor Coregulator DIN-1S in the Caenorhabditis elegans

Dauer Larva. *Genetics* 203(4):1763-1776.

85. Narbonne P & Roy R (2006) Inhibition of germline proliferation during C. elegans dauer

development requires PTEN, LKB1 and AMPK signalling. *Development* 133(4):611-619.

86. Wong C, Kadekar P, Jurczak E, & Roy R (2023) Germline stem cell integrity and

quiescence are controlled by an AMPK-dependent neuronal trafficking pathway. *PLoS*

Genet 19(4):e1010716.

87. Derry WB*, et al.* (2007) Regulation of developmental rate and germ cell proliferation in

Caenorhabditis elegans by the p53 gene network. *Cell Death Differ* 14(4):662-670.

88. Vousden KH & Ryan KM (2009) p53 and metabolism. *Nat Rev Cancer* 9(10):691-700.

89. Jones RG*, et al.* (2005) AMP-activated protein kinase induces a p53-dependent metabolic

checkpoint. *Mol Cell* 18(3):283-293.

90. Feng Y, Williams BG, Koumanov F, Wolstenholme AJ, & Holman GD (2013) FGT-1 is the

major glucose transporter in C. elegans and is central to aging pathways. *Biochem J*

456(2):219-229.

91.   Schulz TJ, *et al.* (2007) Glucose restriction extends Caenorhabditis elegans life span by
835   inducing mitochondrial respiration and increasing oxidative stress. *Cell Metab* 6(4):280-
836   293.

837   92.   Walker MD, *et al.* (2021) WormPaths: Caenorhabditis elegans metabolic pathway
838   annotation and visualization. *Genetics* 219(1).

839   93.   Bargmann CI & Horvitz HR (1991) Control of larval development by chemosensory
840   neurons in Caenorhabditis elegans. *Science* 251(4998):1243-1246.

841   94.   Das S, Min S, & Prahlad V (2021) Gene bookmarking by the heat shock transcription factor
842   programs the insulin-like signaling pathway. *Mol Cell* 81(23):4843-4860 e4848.

843   95.   Das S, *et al.* (2020) Serotonin signaling by maternal neurons upon stress ensures progeny
844   survival. *Elife* 9.

845   96.   Tatum MC, *et al.* (2015) Neuronal serotonin release triggers the heat shock response in
846   C. elegans in the absence of temperature increase. *Curr Biol* 25(2):163-174.

847   97.   Ooi FK & Prahlad V (2017) Olfactory experience primes the heat shock transcription factor
848   HSF-1 to enhance the expression of molecular chaperones in C. elegans. *Sci Signal*
849   10(501).

850   98.   Venkatesh H & Monje M (2017) Neuronal Activity in Ontogeny and Oncology. *Trends*
851   *Cancer* 3(2):89-112.

852   99.   Curry RN & Glasgow SM (2021) The Role of Neurodevelopmental Pathways in Brain
853   Tumors. *Front Cell Dev Biol* 9:659055.

Figure 1

a Egg lay on food, 20ºC, 2 hrs → Place embryos at 25°C → Score dauers 48-72 hrs. later

b

% dauers

N2
ilc-17.1(syb5296)
ilc-17.1(syb5297)
ilc-17.1 rescued; (ilc-17.1p)
ilc-17.1 rescued; (unc-54p)

***   ***

c Wild-type (N2)   1mm

d ilc-17.1(syb5296)   1mm

e

□ Control
▨ ilcr-2 RNAi

% dauers

ns

***

N2   ilc-17.1 (syb5296)

f Egg lay +/- Auxin at 20ºC, 4 hrs → Place embryos at 25°C → Score dauers 48-72 hrs later

g

% dauers

□ Control   ▨ 4mM Auxin

***   ***   ns   ns   *   ns

rgef-1p::TIR1 (neuronal)
myo-2p::TIR1 (pharyngeal)
col-10p::TIR1 (hypodermal)
unc-54p::TIR1 (muscle)
eft-3p::TIR1 (pan-somatic)
mex-5p::TIR1 (germ line)

ilcr-2::AID

h   or

24-36 hr larvae hatched without food or on OP50 lawn, 25°C

ilc-17.1::SL2::mCherry   ILC-17.1::HA

No food   i 5µm   j α-HA 5µm

OP50   k 5µm   l α-HA 5µm

Wildtype (Non-transgenic)

Control   m α-HA 5µm   n α-HA 5µm

o KEGG Enrichment
ilc-17.1 vs N2 downregulated

Count
• 20
● 30
● 40
● 50

p.adjust
0.005
0.010
0.015

Mismatch repair
Nucleocytoplasmic transport
Base excision repair
Homologous recombination
Fanconi anemia pathway
Arginine biosynthesis
DNA replication
Alanine, aspartate and glutamate metabolism
Nucleotide excision repair
Terpenoid backbone biosynthesis
mRNA surveillance pathway
ABC transporters
RNA degradation
Ribosome biogenesis in eukaryotes
RNA polymerase
mTOR signaling pathway
Cysteine and methionine metabolism
Basal transcription factors
Biosynthesis of amino acids
Spliceosome

Fold Enrichment

p KEGG Enrichment
ilc-17.1 vs N2 upregulated

Neuroactive ligand-receptor interaction
Folate biosynthesis
Metabolism of xenobiotics by cytochrome P450
Drug metabolism - cytochrome P450
Fatty acid elongation
Pentose and glucuronate interconversions
Tyrosine metabolism
Retinol metabolism
Glutathione metabolism
Biosynthesis of unsaturated fatty acids
Longevity regulating pathway - worm
Drug metabolism - other enzymes
Tryptophan metabolism
Fatty acid degradation
Lysosome
Fatty acid metabolism
Peroxisome
Autophagy - animal
Oxidative phosphorylation
Biosynthesis of cofactors

Count
• 10
● 20
● 30
● 40

p.adjust
0.0005
0.0010
0.0015
0.0020
0.0025

Fold Enrichment

q

col-102   col-36
col-108   col-37
col-114   col-40
col-123   col-43
col-151   col-44
col-158   col-45
col-163   col-50
col-164   col-51
col-183   col-72
col-185   col-83
col-2   col-84
col-35   col-85

Expression

ilc-17.1
ilc-17.1 rescued (unc-54p)
N2

Figure 2

a **25°C**, 48 hrs. post-egg lay

% dauers

***

ilc-17.1   *ilc-17.1; daf-16 (mu86)*   0.0%

b

% larvae (nuclear DAF-16::GFP)

**

*

N2   *ilc-17.1*

20°C, 40 hrs post-egg lay

N2   c   DAF-16::GFP   5µm

ilc-17.1   d   DAF-16::GFP   5µm

e

Relative fold change(mRNA, **25°C**)

□ *sod-3*
▦ *mtl-1*
▬ *lys-7*

*** ** *** *** *** ** ns ***

N2   *ilc-17.1*   *daf-16*   *ilc-17.1; daf-16*   *ilc-17.1 rescued; (unc-54p)*   *ilc-17.1 rescued; (ilc-17.1p)*

f **25°C**, 48 hrs. post-egg lay

% dauers

*** ***

N2   *daf-5 (e1386)*   *ilc-17.1*   *ilc-17.1; daf-5*

0.0%   0.0%

g **25°C**, 48 hrs. post-egg lay

% dauers

*** ***

Control   DA (50 nM)   Control   DA (50 nM)

N2   *ilc-17.1*

0.0%

h **25°C**, 48 hrs. post-egg lay

% dauers

*** ***

N2   *cep-1 (gk138)*   *ilc-17.1*   *ilc-17.1; cep-1*

0.0%   0.25%

i *ilc-17.1*   1mm

j *ilc-17.1; cep-1*   1mm

Figure 3

a

70 kDA — CEP-1::FLAG
50 kDA — Tubulin

1 2 3 4 5 6

Relative fold change

2.5
2
1.5
1
0.5
0

Ctrl | *ilc-17.1* OE (*unc-54p*) | *ilc-17.1* | Irradiated | Ctrl | *cep-1*

*** ** *** *** *** **

RNAi

CEP-1::FLAG

b

25°C, 48 hrs. post-egg lay

% dauers

0.0%

***

N2 | *cep-1(lg12501);* CEP-1::GFP | *cep-1* OE

c

1mm

cep-1 OE

d

1mm

cep-1(lg12501); CEP-1::GFP

e

Overlap significant DEGs
p < 0.0

2651 | 10051 | *cep-1 OE* 5392

ilc-17.1

f

■ N2
■ *ilc-17.1*
■ *cep-1*
■ *ilc-17.1; cep-1*
■ *cep-1* OE
■ *ilc-17.1* OE (*unc-54p*)
■ *ilc-17.1* OE(*unc-54p*); *cep-1* OE
■ *ilc-17.1rescued;* (*ilc-17.1p*)
■ *ilc-17.1rescued;* (*unc54p*)

Relative fold change (mRNA, 25°C)

6
4
2
0

ns *** *** * *** ***

ns *** ** * *** ***

egl-1   *ced-13*

g

egl-1

p53 TSS

5' — Promoter — 3'

+4 to +123

% input (25°C)

.25
.20
.15
.1
.05
0

*** **

Ctrl | *ilc-17.1* | *ilc-17.1 rescued; (unc-54p)*

CEP-1::FLAG

h

ced-13

p53 TSS

5' — Promoter — 3'

-428 to -310

% input (25°C)

.25
.20
.15
.1
.05
0

*** *

Ctrl | *ilc-17.1* | *ilc-17.1 rescued; (unc-54p)*

CEP-1::FLAG

Figure 4

a

25°C, 48 hrs. post-egg lay

% dauers

*** **

Ctrl daf-16 / Ctrl daf-16
RNAi RNAi / RNAi RNAi

N2 | cep-1 OE

b

25°C, 48 hrs. post-egg lay

% dauers

ns ** **

0.0%

N2 (Ctrl), daf-5 (DA), N2 (DA), cep-1 OE, cep-1 OE; daf-5, cep-1 OE (DA)

c

□ sod-3
▨ mtl-1
▦ lys-7

Relative fold change (mRNA, 25°C)

** *** *** *** ** *** *** *** **

ns

N2, ilc-17.1, cep-1 OE, cep-1, ilc-17.1; cep-1

d

□ cki-1
▨ phg-1

Relative fold change (mRNA, 25°C)

* * * * * *

p=.059

N2, ilc-17.1 OE (unc-54p), ilc-17.1, ilc-17.1 rescue; (unc-54p), cep-1 OE, ilc-17.1;cep-1, ilc-17.1 OE (unc-54p); cep-1 OE

e

phg-1   CEP-1/p53

5'— Promoter —3'

-428 to -249

% input (25°C)

* ns

Ctrl, ilc-17.1, ilc-17.1 rescue; (unc-54p)

CEP-1::FLAG

f

25°C, 48 hrs. post-egg lay

% dauers

*** **

N2, phg-1 (ok2741), ilc-17.1, ilc-17.1; phg-1

g

1mm

ilc-17.1; phg-1

Figure 5

Figure 6

a

25°C, 48 hrs. post-egg lay

b

20°C, Adults

apoptotic nuclei:
Acridine Orange
staining